Hyperammonemia in the ICU: Causes, Lactulose, Rifaximin, CRRT

Critical Care

Hyperammonemia in the ICU: Causes, Lactulose, Rifaximin, CRRT

By gomdori, MDReviewed: July 2026Reading time: 12 min

Executive Summary

Hyperammonemia in the ICU is a neurologic emergency with mortality approaching 50 percent when ammonia exceeds 200 µmol/L and rises despite therapy. The most common adult cause is hepatic encephalopathy from cirrhosis or acute liver failure, but valproate-induced hyperammonemia in patients without liver disease is the most missed cause and warrants reflexive ammonia testing in any encephalopathy on valproate, topiramate, or carbamazepine. Rare but catastrophic causes include adult-onset urea cycle defects (especially OTC deficiency unmasked by stress, GI bleed, post-bariatric surgery, or chronic TPN). Diagnostic workup combines arterial ammonia level (must be free-flowing, processed within 30 minutes), liver function, drug levels, BMP, and rule-out of sepsis and reversible triggers. Management combines reversal of triggers (stop valproate, treat sepsis, control GI bleeding, correct hypokalemia/alkalosis), gut lactulose 30–45 mL PO/NG q1-2h titrated to soft stools, rifaximin 550 mg PO BID, nitrogen scavengers (sodium benzoate + phenylacetate IV) for urea cycle defects, and CRRT for refractory severe hyperammonemia (>200 with rising trend). Intermittent hemodialysis is insufficient due to rebound; continuous RRT (CVVHDF) achieves sustained ammonia reduction.
150Severe Threshold (µmol/L)
75%HE as Cause
~15%Valproate-Induced
~50%Mortality NH3 >200 Rising

1. Pathophysiology & Cerebral Toxicity

Ammonia (NH3) is the byproduct of amino acid catabolism plus gut bacterial protein degradation. Under normal physiology the liver clears ammonia via the urea cycle (urea cycle enzymes: CPS1, OTC, ASS1, ASL, ARG1) into urea, which is excreted renally. When the liver cannot clear ammonia — due to hepatic failure, portosystemic shunting, urea cycle enzyme deficiency, or drug-induced inhibition — circulating ammonia rises into the toxic range.

The brain is the principal target of ammonia toxicity. Ammonia crosses the blood-brain barrier and enters astrocytes, where glutamate is conjugated with NH3 by glutamine synthetase to form glutamine. Accumulating glutamine is osmotically active, drawing water into astrocytes, producing astrocyte swelling and ultimately cerebral edema. Mitochondrial dysfunction, oxidative stress, and disrupted neurotransmitter balance compound the injury. Ammonia levels above 200 µmol/L correlate strongly with cerebral edema risk; levels above 300 µmol/L are associated with brain herniation.

Other contributors to encephalopathy in the hyperammonemic patient include hyponatremia, hypoglycemia, sedative effects, sepsis, and uremia in mixed metabolic encephalopathy. Identifying the dominant driver guides therapy.

2. Etiologies: HE, UCD, Valproate, Other

Hepatic encephalopathy (HE) from cirrhosis or acute liver failure is the most common cause in adult ICU patients. Triggers in cirrhotic patients include GI bleeding, infection (especially SBP), constipation, electrolyte abnormalities (hypokalemia drives renal NH3 production), excess dietary protein, sedatives, and noncompliance with lactulose. The West Haven criteria grade HE severity from grade I (mild confusion) to grade IV (coma).

Drug-induced hyperammonemia in patients without underlying liver disease is the most commonly missed cause in adult ICUs. Valproate is the leading offender, producing hyperammonemia by carnitine depletion + urea cycle inhibition. Even therapeutic valproate levels can produce severe hyperammonemia, particularly in patients with subclinical urea cycle defects unmasked by valproate. Topiramate, carbamazepine, glycine-containing TPN, and chemotherapy (5-FU, asparaginase) are other recognized causes.

Urea cycle defects (UCDs) — most commonly ornithine transcarbamylase (OTC) deficiency, X-linked — can present in adulthood unmasked by stress, GI bleed, post-bariatric surgery, or chronic TPN. Plasma amino acid analysis (low citrulline + arginine, high glutamine) and urinary orotic acid distinguish OTC deficiency from other UCDs. The diagnosis matters because nitrogen scavenger therapy (sodium benzoate + sodium phenylacetate IV) plus arginine supplementation is the specific treatment.

Other causes include Reye syndrome (post-viral, ASA-associated; rare since ASA pediatric guidance), organic acidurias (pediatric inborn errors), urease-producing UTI organisms (Proteus, Klebsiella), portosystemic shunts (TIPS, congenital), and primary mitochondrial disease.

Hyperammonemia Severity Stratification Severity scale: Hyperammonemia Severity Stratification Hyperammonemia Severity Stratification Normal <50 µmol/L; no encephalopathy Mild (50-100) Asymptomatic or mild AMS; address triggers Moderate (100-150) Lactulose + rifaximin; investigate cause Severe (150-200) CURRENT Aggressive Rx; prepare CRRT; ICU Critical (>200) Cerebral edema risk; CRRT mandatory Criteria: • Serum NH3 (free-flowing arterial) • Mental status / GCS • Cerebral edema signs • Trend rising vs falling
Hyperammonemia Severity

3. Diagnostic Workup

Arterial ammonia level is the gold standard. Sample must be drawn free-flowing (no tourniquet), placed on ice, and processed within 30 minutes; venous samples have higher artifactual values. Severity thresholds: 50–100 µmol/L mild, 100–150 moderate, 150–200 severe, >200 critical with cerebral edema risk.

Concurrent workup includes liver function panel + INR, complete blood count, basic metabolic panel (rule out hypokalemia + alkalosis driving NH3), arterial blood gas, lactate, drug levels (valproate, antiepileptics), and infection workup (CBC, blood cultures, urinalysis, paracentesis if ascites). When UCD is suspected, plasma amino acids, urine orotic acid, plasma carnitine, and acylcarnitine profile narrow the differential. CT or MRI brain is appropriate for any altered mental status to rule out intracranial pathology and assess for cerebral edema.

Trend of ammonia level matters more than the absolute value. A patient with NH3 280 µmol/L trending down to 200 is faring better than a patient with 220 trending up to 300. Serial ammonia levels every 4 to 6 hours are essential during acute management until a clear trajectory is established.

Hyperammonemia in the ICU — 24h Schedule Medication administration timeline showing 7 medications over 24h Hyperammonemia in the ICU — 24h Schedule 00 02 04 06 08 10 12 14 16 18 20 22 24 Lactulose NG Lactulose retention enema Rifaximin 550mg PO L-carnitine 50mg/kg IV (if VPA) Nitrogen scavengers IV (UCD) continuous CRRT (CVVHDF) if NH3>200 rising continuous Ammonia level q4h Continuous infusion Intermittent IV push / bolus
Hyperammonemia in the ICU — 24h Schedule

4. Treatment Stepwise

Treatment proceeds in three parallel tracks: reverse precipitants, lower ammonia, prevent cerebral injury.

Reverse precipitants. Stop offending drugs (valproate, topiramate). Treat sepsis with appropriate antibiotics. Control GI bleeding and avoid additional protein load from blood. Correct hypokalemia (drives renal NH3 production) and alkalosis (drives NH3 to NH4+ which is freely diffusible). Address constipation. Consider TIPS dysfunction or shunt issue.

Lower ammonia — gut. Lactulose 30–45 mL PO/NG q1-2h titrated to 3 soft stools per day. For grade III-IV HE or comatose patients, add lactulose retention enema 300 mL in 700 mL water rectally q4-6h. Rifaximin 550 mg PO BID reduces gut ammonia production via gut bacteria suppression and adds to lactulose for both acute and prevention. Neomycin 1g q6h is an older alternative but ototoxicity limits use.

Lower ammonia — systemic. Nitrogen scavengers — sodium benzoate + sodium phenylacetate IV (Ammonul) loading + maintenance — are essential for UCD-related hyperammonemia and useful for severe drug-induced cases. Carglumic acid is specific for NAGS deficiency. L-carnitine 50 mg/kg IV q4-6h is helpful for valproate-induced hyperammonemia. Arginine supplementation supports urea cycle function in some UCDs.

CRRT. Continuous RRT (CVVH or CVVHDF) is the most effective way to clear severe hyperammonemia and is indicated for ammonia >200 µmol/L with rising trend despite Rx, rapidly progressive encephalopathy, established cerebral edema, or refractory neonatal/pediatric UCD. Intermittent hemodialysis is insufficient due to rebound. CRRT can clear ammonia at rates of 30–50 µmol/L/hour and is typically continued until ammonia stabilizes below 100 µmol/L.

CRRT activation threshold. Activate CRRT planning when ammonia exceeds 200 µmol/L AND is trending upward despite lactulose + scavengers. Waiting for 300 µmol/L or established cerebral edema costs neurologic outcome.

5. Outcomes & Prevention

Outcomes correlate with peak ammonia level and time to ammonia normalization. Hepatic encephalopathy from cirrhosis with prompt lactulose initiation has 80 percent recovery without permanent neurologic deficit. Severe hyperammonemia (NH3 >300) carries higher mortality (~50 percent) and survivors often have persistent cognitive impairment. UCD-related hyperammonemia in adult presentations has variable outcomes depending on time to specific therapy.

Prevention focuses on chronic management for cirrhotic patients (lifelong lactulose + rifaximin), avoidance of valproate in patients with subclinical urea cycle dysfunction (suspect with elevated baseline ammonia or unexplained encephalopathy on valproate), early recognition + treatment of HE precipitants, and structured screening for adult-onset UCD in patients with recurrent unexplained hyperammonemia.

Pearl

Reflexively check ammonia in any encephalopathic patient on valproate, topiramate, or carbamazepine — drug-induced hyperammonemia is the most missed adult ICU cause. Even therapeutic levels can drive severe hyperammonemia.

Pitfall

Intermittent hemodialysis for severe hyperammonemia produces rebound within hours of stopping. CRRT (CVVHDF) is required for sustained clearance. Plan CRRT when NH3 exceeds 200 with rising trend rather than waiting for established cerebral edema.
When to escalate. Ammonia >200 µmol/L despite optimal lactulose + rifaximin and reversed precipitants — activate CRRT. Suspected UCD (low citrulline + high glutamine) — plasma amino acids + nitrogen scavengers + metabolic specialist. Cerebral edema signs (Cushing reflex, posturing, papilledema) — neurosurgery + ICP monitoring + consider hyperosmolar therapy.
Hyperammonemia in the ICU — Survival Curves Kaplan-Meier survival curve comparing survival probabilities across groups over time Hyperammonemia in the ICU — Survival Curves 0% 25% 50% 75% 100% 0 6 NH3 100-150 NH3 150-200 NH3 200-300 NH3 >300 50% Time (days) Survival Probability
Hyperammonemia in the ICU — Survival Curves
💎 PRACTICE INSIGHTS

6. Practice Insights

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)In ICU hyperammonemia — hepatology, general critical care, and the occasional rare urea cycle defect — the diagnostic workup is more often the limiting step than the treatment. By the time the first ammonia level returns, the patient has often deteriorated and cerebral edema is established.

What the Guideline Misses

Guidelines list lactulose + rifaximin as backbone but understate how hard it is to administer adequate lactulose in the comatose intubated patient — gastric aspiration, large volumes, ileus risk all interfere. A practical response is to give a lactulose retention enema simultaneously with the NG dose for any grade III-IV HE rather than waiting for NG response. The other gap is the threshold for CRRT — a reasonable trigger is to activate CRRT planning when ammonia exceeds 200 and trends upward despite Rx, rather than waiting for 300 or established cerebral edema.

Patterns That Recur

Valproate-induced hyperammonemia in patients with no liver disease is the most missed cause in adult ICUs — encephalopathy attributed to ‘sepsis’ or ‘metabolic’ for hours before someone checks the ammonia. Reflex checking ammonia in any encephalopathy of unclear etiology is worthwhile, especially with valproate or topiramate exposure. The other recurring pattern is post-bariatric or chronic-TPN patients who develop adult-onset urea cycle defect unmasking — rare but real and often catastrophic.

A Bedside Heuristic

When ammonia is elevated and the patient is encephalopathic, the first question is whether NH3 is rising or falling — not the absolute number. A patient at 280 trending down to 200 is doing better than a patient at 220 trending up to 300, even though the snapshot looks worse for the former. Serial ammonia q4-6h until a clear trend is established is the practical approach, and the trend drives the CRRT decision more than the threshold.

47-year-old man on chronic valproate for bipolar disorder, new encephalopathy

A man in his late 40s with bipolar I on valproate 1500 mg daily for 8 years presented with 24 hours of progressive confusion. Initially attributed to UTI; CT head normal; LP normal. By ICU day 1 he was obtunded and intubated. The covering intensivist ordered ammonia — 380 µmol/L. Valproate level was therapeutic 88 mcg/mL. Valproate was held; lactulose 30 mL NG q2h + rectal 300 mL q4h was started, with rifaximin and L-carnitine 50 mg/kg IV q4h added. Ammonia at 24h was 220, at 48h 95. He was extubated day 4, neurologic recovery complete by week 2. He resumed bipolar treatment with lithium instead of valproate.

→ Reflexively check ammonia in any unexplained encephalopathy on valproate, topiramate, or carbamazepine — drug-induced hyperammonemia is the most missed cause in adult ICUs.

Protocol Adjustments Worth Considering

  • Order an ammonia level reflexively in any encephalopathic patient on valproate, topiramate, or carbamazepine even without obvious liver disease — drug-induced hyperammonemia is missed too often.
  • Give simultaneous NG + rectal lactulose for any grade III-IV hepatic encephalopathy rather than waiting for NG response — gastric aspiration and ileus interfere too often with effective oral dosing.
  • Activate CRRT planning when ammonia exceeds 200 and is trending upward despite lactulose + scavengers — waiting for 300 or established cerebral edema costs neurologic outcome.

7. Frequently Asked Questions

When should I check an ammonia level in the ICU?
Check an arterial ammonia level reflexively in any patient with unexplained encephalopathy, particularly if they are on valproate, topiramate, or carbamazepine, even without overt liver disease. Drug-induced hyperammonemia is the most commonly missed cause in adult ICUs. Other indications include known cirrhosis with new or worsening encephalopathy, post-bariatric or chronic TPN patients with altered mental status (consider unmasked urea cycle defect), and any encephalopathy following GI bleeding. The sample must be drawn free-flowing (no tourniquet), placed on ice, and processed within 30 minutes for accuracy.
When is CRRT indicated for hyperammonemia?
Continuous renal replacement therapy (CVVH or CVVHDF) is indicated for ammonia greater than 200 µmol/L with rising trend despite optimal medical therapy (lactulose + rifaximin + reversed precipitants), rapidly progressive encephalopathy regardless of absolute level, established cerebral edema, or refractory urea cycle defect presentations. Intermittent hemodialysis is insufficient because ammonia rebounds within hours of stopping. CRRT achieves sustained clearance of 30 to 50 µmol/L per hour and is typically continued until ammonia stabilizes below 100 µmol/L. Activate CRRT planning early — waiting for ammonia greater than 300 or established cerebral edema costs neurologic outcome.
What is the role of L-carnitine in valproate-induced hyperammonemia?
L-carnitine 50 mg/kg IV every 4 to 6 hours is the specific antidote for valproate-induced hyperammonemia. Valproate depletes carnitine, which is required for fatty acid oxidation and urea cycle function. Carnitine repletion restores urea cycle enzyme activity (particularly CPS1) and accelerates ammonia clearance. L-carnitine should be added to lactulose and rifaximin for any valproate-related hyperammonemia, with concurrent valproate discontinuation. Patients with chronic valproate exposure may have persistent low carnitine levels that warrant ongoing oral supplementation if the medication cannot be discontinued.

Leave a Reply

Your email address will not be published. Required fields are marked *